retatrutide glp-1 gip glucagon triple agonist phase 3 2025 Dual and Triple Gut Peptide Agonists retatrutide triple agonist glp-1 gip

J Diabetes 7:584588 [DOI] [PubMed] [Google Scholar] 67.Wen B, Zhao L, Zhao H, Wang X (2018) Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis

The World Obesity Federation states that nearly 2.8 billion people worldwide are affected by obesity 1

In the Prime Therapeutic study cited above, only one in four patients were still on Wegovy or Ozempic two years later

The hepatic benefits of GLP-1RAs are partially independent of weight loss, as demonstrated in clinical trials in which matched weight loss achieved by lifestyle intervention did not replicate the full metabolic improvements seen with GLP-1RA therapy, including enhanced glucose handling and decreased de novo lipogenesis (20)

To learn more about this report, download the PDF brochure Rising prevalence of obese and overweight population to propel the obesity drugs market demand Obesity is one of the leading contributors to a number of non-communicable diseases including heart disease, stroke and diabetes